Common side effects include nausea and Eli Lillys triple agonist, retatrutide, demonstrated an average weight loss of 16.8% in a Phase 3 trial for the treatment of type 2 diabetes, the company announced today
Errors in conversion between pen and vial systems can create weeks of subtherapeutic or supratherapeutic dosing that disrupts the entire treatment timeline
Arvat E, Maccario M, Di Vito L, et al
However, the current evidence base is largely preclinical, and no large-scale human clinical trials have confirmed its efficacy
Synergy tests with SynergyFinder: melanoma cells were treated with a combination of BRAF, MEK- and CDK- inhibitors at 8 concentrations (in a 1:2 or 1:1.5 dilution range) based on their respective IC 50 values